EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer

Elena Conca, Daniele Lorenzini, Emanuela Minna, Luca Agnelli, Matteo Duca, Marco Gentili, Beatrice Bodini, Maggie Polignano, Mara Mantiero, Silvia Damian, Andrea Devecchi, Gianpaolo Dagrada und 16 weitere

Frontiers in Oncology · 06.08.2025 · 15

DOI: 10.3389/fonc.2025.1633410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 06.08.2025. Verfasst von Elena Conca und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ovarian cancer (OC) is one of the leading causes of cancer-related death in women worldwide. Treatment with PARP-inhibitors has significantly improved survival in patients with high-grade serous cancer (HGSC) bearing BRCA1/2 mutations (~22% of the cases), and/or homologous recombination deficiency (HRD, ~50%). Unfortunately, limited therapeutic alternatives are available for BRCA1/2 wild type/HR proficient HGSC patients, who usually exhibit resistance to standard treatments and poor prognosis.

Methods

Herein, we present the results of a comprehensive genomic profiling (CGP) analysis using the Oncomine Comprehensive Assay® (OCA) Plus in a consecutive retrospective cohort of 102 HGSC patients characterized in our institution.

Results

Genomic instability, measured by Genomic Instability Metric (GIM) >16, was found in 40% of the cases and was significantly associated with BRCA1/2 mutations (p=0.009), with a better prognosis in terms of recurrence-free survival (p=0.01). CCNE1 amplification was observed in 29% of cases and was negatively correlated with BRCA1/2 mutations (p=0.001), without any association with GIM, supporting CCNE1 as a strong and independent driver of tumorigenesis. Additionally, CCNE1 amplification was validated with fluorescent in situ hybridization (FISH), supporting the analytical robustness of NGS data (rho=0.93), and investigated by immunohistochemistry (IHC), revealing that CCNE1 protein overexpression was observed in the absence of gene amplification in 45% of cases.

Discussion

Our real-world study supports the clinical utility of the GIM metric and the analytical validity of CCNE1 amplification, a new promising biomarker for personalizing treatment in HR proficient HGSC patients. The discordance between CCNE1 amplification and protein expression raises intriguing questions about the mechanisms of CCNE1 -driven tumorigenesis and warrants further investigation.

Schlagwörter

Stichwörter der Autor:innen

CCNE1 amplificationcomprehensive genomic profiling (CGP)high-grade serous ovarian cancer (HGSC)homologous recombination deficiency (HRD) scoreprecision oncology cancer

Autor:innen und Institutionen

  • Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.
  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
  • Department of Pathology and Laboratory Medicine, Pathology Unit 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
  • Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Zitieren

APA

Conca, E., Lorenzini, D., Minna, E., Agnelli, L., Duca, M., Gentili, M., Bodini, B., Polignano, M., Mantiero, M., Damian, S., Devecchi, A., Dagrada, G., Carminati, R., Ardore, A., Barbetta, F., Da Chuna, N. B., Guerrizio, A., Busico, A., Capone, I., …, & Pruneri, G. (2025). Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1633410

Vancouver

Conca E, Lorenzini D, Minna E, Agnelli L, Duca M, Gentili M, et al. Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1633410

BibTeX
@article{Conca2025,
  author = {Conca, Elena and Lorenzini, Daniele and Minna, Emanuela and Agnelli, Luca and Duca, Matteo and Gentili, Marco and Bodini, Beatrice and Polignano, Maggie and Mantiero, Mara and Damian, Silvia and Devecchi, Andrea and Dagrada, Gianpaolo and Carminati, Rita and Ardore, Alice and Barbetta, Francesca and Da Chuna, Nathalia Brito and Guerrizio, Andrea and Busico, Adele and Capone, Iolanda and Piccolo, Alberta and Tamborini, Elena and Perrone, Federica and Milione, Massimo and Paolini, Biagio and Vingiani, Andrea and Raspagliesi, Francesco and De Braud, Filippo and Pruneri, Giancarlo},
  title = {Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1633410}
}
Kostenlos starten →